Literature DB >> 22623087

Management of ruptured brain arteriovenous malformations.

Brad E Zacharia1, Kerry A Vaughan, Adam Jacoby, Zachary L Hickman, Daniel Bodmer, E Sander Connolly.   

Abstract

Intracranial arteriovenous malformations (AVMs) are a common cause of stroke in younger patients, and often present as intracerebral hemorrhages (ICH), associated with 10 % to 30 % mortality. Patients who present with a hemorrhage from an AVM should be initially stabilized according to acute management guidelines for ICH. The characteristics of a lesion including its size, location in eloquent tissue, and high-risk features will influence risk of rupture, prognosis, as well as help guide management decisions. Given that rupture is associated with an increased risk of 6 % re-rupture in the year following the initial hemorrhage, versus 1 % to 3 % predicted annual risk in non-ruptured lesions only, definitive treatment is encouraged after ICH stabilization. A rest period of 2 to 6 weeks after hemorrhage is recommended before definitive treatment to avoid disrupting friable parenchyma and the hematoma. Treatment may consist of endovascular embolization, surgical resection, radiosurgery, or a combination of these three interventions based on the lesion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623087     DOI: 10.1007/s11883-012-0257-9

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  43 in total

Review 1.  Selection of treatment modalities or observation of arteriovenous malformations.

Authors:  John C Barr; Christopher S Ogilvy
Journal:  Neurosurg Clin N Am       Date:  2012-01       Impact factor: 2.509

2.  Cooling in intracerebral hemorrhage (CINCH) trial: protocol of a randomized German-Austrian clinical trial.

Authors:  Rainer Kollmar; Eric Juettler; Hagen B Huttner; Arnd Dörfler; Dimitre Staykov; Bernd Kallmuenzer; Erich Schmutzhard; Stefan Schwab; Gregor Broessner
Journal:  Int J Stroke       Date:  2012-02       Impact factor: 5.266

3.  Arteriovenous malformations of the brain. A long-term clinical study.

Authors:  D M Forster; L Steiner; S Håkanson
Journal:  J Neurosurg       Date:  1972-11       Impact factor: 5.115

4.  Admission to a neurologic/neurosurgical intensive care unit is associated with reduced mortality rate after intracerebral hemorrhage.

Authors:  M N Diringer; D F Edwards
Journal:  Crit Care Med       Date:  2001-03       Impact factor: 7.598

5.  Age-related spontaneous intracerebral hematoma in a German community.

Authors:  H Schütz; R H Bödeker; M Damian; P Krack; W Dorndorf
Journal:  Stroke       Date:  1990-10       Impact factor: 7.914

6.  Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Lewis B Morgenstern; J Claude Hemphill; Craig Anderson; Kyra Becker; Joseph P Broderick; E Sander Connolly; Steven M Greenberg; James N Huang; R Loch MacDonald; Steven R Messé; Pamela H Mitchell; Magdy Selim; Rafael J Tamargo
Journal:  Stroke       Date:  2010-07-22       Impact factor: 7.914

Review 7.  A systematic review of the frequency and prognosis of arteriovenous malformations of the brain in adults.

Authors:  R Al-Shahi; C Warlow
Journal:  Brain       Date:  2001-10       Impact factor: 13.501

8.  The ARUBA trial: current status, future hopes.

Authors:  J P Mohr; Alan J Moskowitz; Christian Stapf; Andreas Hartmann; Karen Lord; Steven M Marshall; Henning Mast; Ellen Moquete; Claudia Scala Moy; Michael Parides; John Pile-Spellman; Rustam Al-Shahi Salman; Alan Weinberg; William L Young; Alejandrina Estevez; Inam Kureshi; Jonathan L Brisman
Journal:  Stroke       Date:  2010-07-15       Impact factor: 7.914

9.  Early surgery for ruptured cerebral arteriovenous malformations.

Authors:  J Kuhmonen; A Piippo; K Väärt; A Karatas; K Ishii; P Winkler; M Niemelä; M Porras; J Hernesniemi
Journal:  Acta Neurochir Suppl       Date:  2005

Review 10.  Intracerebral hemorrhage: pathophysiology and management.

Authors:  M N Diringer
Journal:  Crit Care Med       Date:  1993-10       Impact factor: 7.598

View more
  8 in total

Review 1.  Cerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies?

Authors:  Kellen E Haley; Steven M Greenberg; M Edip Gurol
Journal:  Curr Cardiol Rep       Date:  2013-12       Impact factor: 2.931

Review 2.  Endovascular management of arteriovenous malformations of the brain.

Authors:  Charles A Bruno; Philip M Meyers
Journal:  Interv Neurol       Date:  2013-09

3.  Radiologic and histologic consequences of radiosurgery for brain tumors.

Authors:  Ahmed Alomari; Philipp J Rauch; Maria Orsaria; Frank J Minja; Veronica L Chiang; Alexander O Vortmeyer
Journal:  J Neurooncol       Date:  2014-01-18       Impact factor: 4.130

Review 4.  Targeted endovascular treatment for ruptured brain arteriovenous malformations.

Authors:  Kun Hou; Kan Xu; Xuan Chen; Tiefeng Ji; Yunbao Guo; Jinlu Yu
Journal:  Neurosurg Rev       Date:  2019-11-13       Impact factor: 3.042

5.  Acute spontaneous subdural hematoma secondary to ruptured arteriovenous malformation: A rare entity.

Authors:  Hung Dinh Kieu; Tam Duc Le; Tan Minh Hoang
Journal:  Ann Med Surg (Lond)       Date:  2021-07-27

6.  Ruptured Brain Arteriovenous Malformations: Surgical Timing and Outcomes-A Retrospective Study of 25 Cases.

Authors:  Alessandro Di Bartolomeo; Anthony Kevin Scafa; Marco Giugliano; Demo Eugenio Dugoni; Andrea Gennaro Ruggeri; Roberto Delfini
Journal:  J Neurosci Rural Pract       Date:  2020-11-04

7.  Multimodal Treatment of Pediatric Ruptured Brain Arteriovenous Malformations: A Single-Center Study.

Authors:  Lukasz Antkowiak; Monika Putz; Marta Rogalska; Marek Mandera
Journal:  Children (Basel)       Date:  2021-03-11

8.  The Potential Value of 320-Row Computed Tomography Angiography in Digital Subtraction Angiography-Negative Spontaneous Subarachnoid Hemorrhage Patients.

Authors:  Shengfeng Wu
Journal:  J Comput Assist Tomogr       Date:  2022 Mar-Apr 01       Impact factor: 1.826

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.